Small Cell Lung Cancer – Diverse First-In-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease

Pages: 55 Published: September 30, 2019 Report Code: GDHC497FP

Initially considered a curable disease due to substantial sensitivity to chemotherapy, small cell lung cancer (SCLC) remains a fatal disease with a poor outcome, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of numerous targeted therapies, the field of SCLC has seen little advancement, and the standard of care (SOC) for several decades has been platinum-etoposide chemotherapy. Limited tumor tissue for translational research, poor understanding of the mechanisms underlying disease biology, and therapeutic resistance are major factors impeding the discovery of effective drugs, including targeted therapies in SCLC, proving a major clinical need for patients.
To date, there have been three targeted therapies approved to treat SCLC, Bristol-Myers Squibb’s Opdivo (nivolumab), Roche’s Tecentriq (atezolizumab), and Merck & Co.’s Keytruda (pembrolizumab) which were approved by the FDA in August 2018, March 2019 and June 2019, respectively. The recent approval of targeted and immuno-therapies for SCLC will generate a new maintenance setting following chemotherapy in SCLC. Following the approval of these new agents, relapsed/refractory patients are expected to have significantly improved therapeutic options. The increased prescription of branded therapies in treatment-naïve and advanced patients will be the primary impetus driving the substantial growth in the SCLC market.


There are 165 pipeline programs in active development for SCLC. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?

Which molecular target classes are prominently represented in the first-in-class SCLC pipeline? Which first-in-class targets have been identified as most promising for the treatment of SCLC? How does the distribution of target classes differ in terms of development stage?

Across the SCLC landscape, there are 118 active companies. Which companies have formed partnerships? Which companies have first-in-class assets in development with no prior deal involvement?

Reasons to Buy

Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology. Visualize the composition of the SCLC market in terms of dominant molecule types and molecular targets.

Analyze and compare the SCLC pipeline and stratify by stage of development, molecule type, and molecular target.

Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class programs have been assessed and ranked according to their clinical potential. Promising first-in-class targets have been reviewed in greater detail.

Recognize commercial opportunities by identifying first-in-class pipeline programs for SCLC that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class SCLC programs.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Small Cell Lung Cancer: Executive Summary

2.1 Pipeline Holds Some Potential for the Approval of More Targeted Therapies

2.2 High Levels of First-in-Class Innovation

2.3 Need for Disease-Modifying Pharmacotherapies

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.2 Classification or Staging Systems

4.3 Sustained Innovation in SCLC

4.4 Epidemiology for SCLC

4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation

5.1 Overview

5.2 Pipeline by Stage of Development and Molecule Type

5.3 Pipeline by Molecular Target

5.4 Comparative Distribution of Programs Between SCLC Market and Pipeline by Therapeutic Target Family

5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class

5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs

5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline

6 First-in-Class Molecular Target Evaluation

6.1 Overview

6.2 Pipeline Programs Targeting GTPase KRAS

6.3 Pipeline Programs Targeting Interleukin 2 Receptor Beta and Gamma

6.4 Pipeline Programs Targeting Heat Shock Protein 90

6.5 Pipeline Programs Targeting Serine/Threonine Protein Kinase AKT (AKT1, AKT2, AKT3)

6.6 Pipeline Programs Targeting Hepatitis A Virus Cellular Receptor 2

6.7 Pipeline Programs Targeting Serine/Threonine-Protein Kinase ATR

6.8 Pipeline Programs Targeting Protein Phosphatase 2A

6.9 Pipeline Programs Targeting Histone-lysine N-methyltransferase EZH2

6.10 Pipeline Programs Targeting Lymphocyte Activation Gene 3 Protein

7 Key Players and Deals

7.1 Overview

7.1.1 Allogene Therapeutics Enters into Licensing Agreement with Cellectis

7.1.2 Amgen and MD Anderson Enter Two Collaboration Agreements Across Various Cancer Types

7.1.3 MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center

8 Appendix

8.1 Bibliography

8.2 Abbreviations

8.3 Methodology

8.3.1 Market Analysis

8.3.2 Overall Pipeline Analysis

8.3.3 First-in-Class Pipeline Analysis

8.3.4 First-in-Class Matrix Assessment

8.3.5 First-in-Class Molecular Target Evaluation

8.3.6 Key Players and Deals

8.4 About the Authors

8.4.1 Analyst

8.4.2 Therapy Area Director

8.4.3 Global Director of Therapy Analysis and Epidemiology

8.4.4 Global Head and EVP of Healthcare Operations and Strategy

8.5 About GlobalData

8.6 Contact Us

8.7 Disclaimer

List of Tables

Table 1: Definitions Used in TNM Classification and Clinical Staging System in Lung Cancer

Table 2: AJCC Staging of Lung Cancer

Table 3: SCLC Diagnosed Prevalent Cases (N), Thousands, 20142024

List of Figures

Figure 1: SCLC, Global Market by Molecular Target and Molecule Type, 2019

Figure 2: SCLC, Global, Pipeline by Stage of Development and Molecule Type, 2019

Figure 3: SCLC, Global, Pipeline by Molecular Target and Stage of Development, 2019

Figure 4: SCLC, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019

Figure 5: SCLC, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019

Figure 6: SCLC, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019

Figure 7: SCLC, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019


Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Enquire Before Buying

Request a Free Sample


“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods